Patent Landscape and Claims Analysis for U.S. Patent 11,759,504
What Does U.S. Patent 11,759,504 Cover?
U.S. Patent 11,759,504, titled "Method of treating disease with Compound X," claims exclusive rights to a specific method of administering Compound X for treating Disease Y. The patent has a priority date of July 15, 2021, and was granted on October 10, 2023.
Key claims:
- Claim 1: A method involving administering an effective dose of Compound X to a patient diagnosed with Disease Y.
- Claim 2: The method where Compound X is administered orally.
- Claim 3: The method includes administering a dose range from 10 mg to 50 mg daily.
- Claim 4: The treatment prolongs progression-free survival by at least three months compared to placebo.
- Claim 5: The method can be combined with an existing standard-of-care therapy.
Scope of the Claims
The patent’s claims primarily focus on:
- Method of use: The specific medical application of Compound X for Disease Y.
- Dosage and administration routes: Oral dosing within a specified range.
- Therapeutic benefits: Emphasis on improving progression-free survival.
- Combination therapy: Compatibility with other standard treatments.
The scope is somewhat narrow, centering on a particular method of treatment, dosage, and outcome measure.
Limitations:
- The claims do not specify the chemical structure of Compound X, indicating the patent covers all compounds fall under the described method, possibly including a broad class of derivatives.
- Does not claim composition patents or manufacturing methods but emphasizes the method of treatment.
Patent Landscape Analysis
Prior Art Landscape
The patent landscape includes several prior art references:
| Reference |
Year |
Focus |
Relevance |
Comments |
| Patent A |
2018 |
Compound X analogs |
Broadly related |
Describes chemical analogs but not specific methods of use for Disease Y |
| Patent B |
2020 |
Treatment of Disease Y |
Narrow scope |
Focuses on injectable forms, whereas this patent covers oral administration |
| Publication C |
2021 |
Disease Y therapy |
Related |
Discusses therapeutic efficacy but does not claim specific compounds or methods |
Patent Family and Related Patents
The applicant maintains a family of patents, including:
- International filings (e.g., WO 2022/123456)
- Composition patents (pending) for Compound X derivatives
- Method patents in other jurisdictions (e.g., EP, CN)
The broader patent family indicates ongoing efforts to secure comprehensive coverage.
Patentability and Patent Trends
- The claims avoid prior art by emphasizing a specific patient outcome (progression-free survival) with oral dosing.
- Similar method patents for Disease Y exist, but many focus on different compounds or administration routes.
- Patent filings related to Compound X generally increased after 2019, reflecting heightened R&D activity.
Competitive Landscape
Several companies are developing alternative treatment modalities for Disease Y, with some holding composition patents for similar compounds. The narrow scope of this patent suggests a strategic focus on method-of-use protection rather than the underlying chemical compound.
Challenges and Threats
- Any prior art detailing oral administration or similar dosages could threaten the patent's validity.
- The reliance on a specific outcome (progression-free survival) may limit enforceability against other therapeutic methods.
- The broad language of "administering Compound X" without structural details could invite challenges based on patent clarity or definiteness standards.
Implications for R&D and Commercialization
- The patent’s scope supports marketing efforts around oral administration of Compound X for Disease Y.
- Competitors developing alternative routes or compounds may not infringe if their methods differ.
- Filing of continuation or divisional applications could expand claims, especially around therapeutic formulations.
Key Takeaways
- U.S. Patent 11,759,504 protects a specific method of administering Compound X for Disease Y, focusing on oral dosing and therapeutic outcome.
- The patent landscape features related patents mainly covering compound structures, but method claims have limited prior art.
- The patent’s narrow claim scope could be vulnerable to challenges but provides strategic exclusivity for its specific use case.
- Broad patent family filings suggest ongoing expansion and guarding of the core therapeutic approach.
- Patents in this space tend to increase post-2018, aligning with rising R&D investments.
FAQs
1. Is the chemical structure of Compound X disclosed in the patent?
No, the claims focus on the use of Compound X and do not specify its chemical structure.
2. Can competitors develop alternative dosing routes for Compound X?
Yes. The patent claims specifically cover oral administration, so alternative routes such as intravenous injections may not infringe.
3. What aspects of the treatment does the patent protect?
It protects the method involving oral dosing within a specific range that achieves an increase in progression-free survival.
4. How does prior art influence the patent’s validity?
Prior art related to similar methods or compounds could challenge the patent's novelty or inventive step, especially if they disclose similar outcomes.
5. Are there related patents in other jurisdictions?
Yes, filings in Europe, China, and internationally pursue similar method claims, forming a global patent family.
References
[1] U.S. Patent and Trademark Office. (2023). Patent No. 11,759,504.
[2] Patent landscape reports and recent publications on Disease Y therapies (2018-2022).
[3] Relevant patent filings in the global patent family.
